User profiles for EMANUEL F. PETRICOIN

Emanuel Petricoin

George Mason University
Verified email at gmu.edu
Cited by 54445

Use of proteomic patterns in serum to identify ovarian cancer

EF Petricoin, AM Ardekani, BA Hitt, PJ Levine… - The lancet, 2002 - thelancet.com
Background New technologies for the detection of early-stage ovarian cancer are urgently
needed. Pathological changes within an organ might be reflected in proteomic patterns in …

[PDF][PDF] Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse

SR Hingorani, EF Petricoin, A Maitra, V Rajapakse… - Cancer cell, 2003 - cell.com
To evaluate the role of oncogenic RAS mutations in pancreatic tumorigenesis, we directed
endogenous expression of KRAS G12D to progenitor cells of the mouse pancreas. We find …

Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front

…, MR Emmert-Buck, MJ Roth, EF Petricoin III… - Oncogene, 2001 - nature.com
Protein arrays are described for screening of molecular markers and pathway targets in patient
matched human tissue during disease progression. In contrast to previous protein arrays …

Proteomic applications for the early detection of cancer

JD Wulfkuhle, LA Liotta, EF Petricoin - Nature reviews cancer, 2003 - nature.com
The ability of physicians to effectively treat and cure cancer is directly dependent on their ability
to detect cancers at their earliest stages. Proteomic analyses of early-stage cancers have …

Serum proteomic patterns for detection of prostate cancer

EF Petricoin III, DK Ornstein… - Journal of the …, 2002 - academic.oup.com
Pathologic states within the prostate may be reflected by changes in serum proteomic patterns.
To test this hypothesis, we analyzed serum proteomic mass spectra with a bioinformatics …

Laser-capture microdissection

…, W Zhou, G Coukos, DH Geho, EF Petricoin III… - Nature protocols, 2006 - nature.com
Deciphering the cellular and molecular interactions that drive disease within the tissue
microenvironment holds promise for discovering drug targets of the future. In order to recapitulate …

Clinical proteomics: translating benchside promise into bedside reality

EF Petricoin, KC Zoon, EC Kohn, JC Barrett… - Nature reviews Drug …, 2002 - nature.com
The ultimate goal of proteomics is to characterize the information flow through protein
networks. This information can be a cause, or a consequence, of disease processes. Clinical …

[HTML][HTML] 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers

…, MR Emmert-Buck, LA Liotta, EF Petricoin… - Molecular & Cellular …, 2002 - ASBMB
The reproducibility of conventional two-dimensional (2D) gel electrophoresis can be improved
using differential in-gel electrophoresis (DIGE), a new emerging technology for proteomic …

Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer

…, AK Witkiewicz, ES Knudsen, EF Petricoin III… - Nature medicine, 2019 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) is characterized by KRAS- and autophagy-dependent
tumorigenic growth, but the role of KRAS in supporting autophagy has not been …

[PDF][PDF] Protein microarrays: meeting analytical challenges for clinical applications

…, PJ Munson, L Young, J Wulfkuhle, EF Petricoin - Cancer cell, 2003 - cell.com
Protein microarrays, one emerging class of proteomic technologies, have broad applications
for discovery and quantitative analysis. A rapidly expanding use of this technology is the …